156 related articles for article (PubMed ID: 36870800)
1. Role of Artificial Intelligence in PET/CT Imaging for Management of Lymphoma.
Veziroglu EM; Farhadi F; Hasani N; Nikpanah M; Roschewski M; Summers RM; Saboury B
Semin Nucl Med; 2023 May; 53(3):426-448. PubMed ID: 36870800
[TBL] [Abstract][Full Text] [Related]
2.
Girum KB; Rebaud L; Cottereau AS; Meignan M; Clerc J; Vercellino L; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
J Nucl Med; 2022 Dec; 63(12):1925-1932. PubMed ID: 35710733
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a convolution neural network for baseline total tumor metabolic volume on [
Karimdjee M; Delaby G; Huglo D; Baillet C; Willaume A; Dujardin S; Bailliez A
Eur Radiol; 2023 May; 33(5):3386-3395. PubMed ID: 36600126
[TBL] [Abstract][Full Text] [Related]
4. Metabolic tumour volume in Hodgkin lymphoma-A comparison between manual and AI-based analysis.
Sadik M; Barrington SF; Trägårdh E; Saboury B; Nielsen AL; Jakobsen AL; Gongora JLL; Urdaneta JL; Kumar R; Edenbrandt L
Clin Physiol Funct Imaging; 2024 May; 44(3):220-227. PubMed ID: 38011940
[TBL] [Abstract][Full Text] [Related]
5. Molecular Imaging of Lymphoma: Future Directions and Perspectives.
Pomykala KL; Fendler WP; Vermesh O; Umutlu L; Herrmann K; Seifert R
Semin Nucl Med; 2023 May; 53(3):449-456. PubMed ID: 36344325
[TBL] [Abstract][Full Text] [Related]
6. Deep-Learning
Capobianco N; Meignan M; Cottereau AS; Vercellino L; Sibille L; Spottiswoode B; Zuehlsdorff S; Casasnovas O; Thieblemont C; Buvat I
J Nucl Med; 2021 Jan; 62(1):30-36. PubMed ID: 32532925
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT in the management of lymphomas: current status and future directions.
El-Galaly TC; Villa D; Gormsen LC; Baech J; Lo A; Cheah CY
J Intern Med; 2018 Oct; 284(4):358-376. PubMed ID: 29989234
[TBL] [Abstract][Full Text] [Related]
8. Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.
Blanc-Durand P; Jégou S; Kanoun S; Berriolo-Riedinger A; Bodet-Milin C; Kraeber-Bodéré F; Carlier T; Le Gouill S; Casasnovas RO; Meignan M; Itti E
Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1362-1370. PubMed ID: 33097974
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography/computed tomography in the management of Hodgkin and B-cell non-Hodgkin lymphoma: An update.
Juweid ME; Mueller M; Alhouri A; A-Risheq MZ; Mottaghy FM
Cancer; 2021 Oct; 127(20):3727-3741. PubMed ID: 34286864
[No Abstract] [Full Text] [Related]
10. Prognostic value of baseline
Zhou Y; Hong Z; Zhou M; Sang S; Zhang B; Li J; Li Q; Wu Y; Deng S
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):87-95. PubMed ID: 31880103
[TBL] [Abstract][Full Text] [Related]
11. Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?
El-Galaly TC; Villa D; Cheah CY; Gormsen LC
Br J Haematol; 2022 Apr; 197(2):139-155. PubMed ID: 35037240
[TBL] [Abstract][Full Text] [Related]
12.
Sibille L; Seifert R; Avramovic N; Vehren T; Spottiswoode B; Zuehlsdorff S; Schäfers M
Radiology; 2020 Feb; 294(2):445-452. PubMed ID: 31821122
[TBL] [Abstract][Full Text] [Related]
13. Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma.
Cottereau AS; Hapdey S; Chartier L; Modzelewski R; Casasnovas O; Itti E; Tilly H; Vera P; Meignan MA; Becker S
J Nucl Med; 2017 Feb; 58(2):276-281. PubMed ID: 27754905
[TBL] [Abstract][Full Text] [Related]
14. When should FDG-PET be used in the modern management of lymphoma?
Barrington SF; Mikhaeel NG
Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
[TBL] [Abstract][Full Text] [Related]
15. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
16. Usual and unusual pitfalls of 18F-FDG-PET/CT in lymphoma after treatment: a pictorial review.
Dubreuil J; Salles G; Bozzetto J; Tordo J; Djaïleb L; Berriolo-Riedinger A; Leenhardt J; Giammarile F; Meignan M; Skanjeti A
Nucl Med Commun; 2017 Jul; 38(7):563-576. PubMed ID: 28570287
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of pretreatment 18F-FDG PET/CT in primary brain lymphoma.
Albano D; Bertoli M; Battistotti M; Rodella C; Statuto M; Giubbini R; Bertagna F
Ann Nucl Med; 2018 Oct; 32(8):532-541. PubMed ID: 29982990
[TBL] [Abstract][Full Text] [Related]
18. Full automation of total metabolic tumor volume from FDG-PET/CT in DLBCL for baseline risk assessments.
Jemaa S; Paulson JN; Hutchings M; Kostakoglu L; Trotman J; Tracy S; de Crespigny A; Carano RAD; El-Galaly TC; Nielsen TG; Bengtsson T
Cancer Imaging; 2022 Aug; 22(1):39. PubMed ID: 35962459
[TBL] [Abstract][Full Text] [Related]
19. Total tumor burden in lymphoma - an evolving strong prognostic parameter.
Meignan M; Cottereau AS; Specht L; Mikhaeel NG
Br J Radiol; 2021 Nov; 94(1127):20210448. PubMed ID: 34379496
[TBL] [Abstract][Full Text] [Related]
20. Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions).
Hasani N; Paravastu SS; Farhadi F; Yousefirizi F; Morris MA; Rahmim A; Roschewski M; Summers RM; Saboury B
PET Clin; 2022 Jan; 17(1):145-174. PubMed ID: 34809864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
